{"content":"<li class=\"n-box-item date-title\" data-end=\"1576904399\" data-start=\"1576818000\" data-txt=\"Monday, December 23, 2019\">Friday, December 20, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3527980\" data-ts=\"1576882236\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527980-mrns-play-quad-and-armp-among-notable-after-hours-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MRNS, PLAY, QUAD and ARMP among notable after hours movers</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CRTX' title='Cortexyme, Inc.'>CRTX</a> <font color=\"green\">+8%</font>. <a href='https://seekingalpha.com/symbol/BANC' title='Banc of California, Inc.'>BANC</a> <font color=\"green\">+5.3%</font>. <a href='https://seekingalpha.com/symbol/RESI' title='Front Yard Residential Corporation'>RESI</a> <font color=\"green\">+3.9%</font>. <a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color=\"green\">+3.4%</font>. <a href='https://seekingalpha.com/symbol/QUAD' title='Quad/Graphics, Inc.'>QUAD</a> <font color=\"green\">+2.8%</font>.</li><li><b>Losers: </b><a href='https://seekingalpha.com/symbol/ARMP' title='Armata Pharmaceuticals, Inc.'>ARMP</a> <font color=\"red\">-8.5%</font>.  <a href='https://seekingalpha.com/symbol/IDYA' title='IDEAYA Biosciences, Inc.'>IDYA</a> <font color=\"red\">-6.5%</font>. <a href='https://seekingalpha.com/symbol/OSMT' title='Osmotica Pharmaceuticals plc'>OSMT</a> <font color=\"red\">-4.3%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals, Inc.'>MRNS</a> <font color=\"red\">-4.2%</font>. <a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio, Inc.'>ANAB</a> <font color=\"red\">-3.7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527980\" data-linked=\"MRNS, PLAY, QUAD and ARMP among notable after hours movers\" data-tweet=\"$CRTX $BANC $RESI - MRNS, PLAY, QUAD and ARMP among notable after hours movers https://seekingalpha.com/news/3527980-mrns-play-quad-and-armp-among-notable-after-hours-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527980-mrns-play-quad-and-armp-among-notable-after-hours-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527958\" data-ts=\"1576876883\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTO\" target=\"_blank\">PRTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527958-proteon-therapeutics-nixes-equity-offering-shares-up-17-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteon Therapeutics nixes equity offering; shares up 17% after hours</a></h4><ul><li>Citing market conditions, Proteon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTO' title='Proteon Therapeutics, Inc.'>PRTO</a>) has decided to <a href=\"https://www.sec.gov/Archives/edgar/data/1359931/000110465919074969/a19-26707_1rw.htm\" target=\"_blank\">withdraw its registration</a> for a public offering of up $50M of common stock.</li><li>Shares up <font color=\"green\">17%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527958\" data-linked=\"Proteon Therapeutics nixes equity offering; shares up 17% after hours\" data-tweet=\"$PRTO - Proteon Therapeutics nixes equity offering; shares up 17% after hours https://seekingalpha.com/news/3527958-proteon-therapeutics-nixes-equity-offering-shares-up-17-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3527958-proteon-therapeutics-nixes-equity-offering-shares-up-17-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527934\" data-ts=\"1576875532\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDFN\" target=\"_blank\">RDFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527934-redfin-gains-firm-praises-fee-increase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Redfin gains as firm praises fee increase</a></h4><ul><li>Data analytics firm YipitData says Redfin's (NASDAQ:<a href='https://seekingalpha.com/symbol/RDFN' title='Redfin Corporation'>RDFN</a>) brokerage revenue growth should see significant upside after the company raised its home seller listing fee to 1.5%</li><li>RDFN shares are <font color=\"green\">up 1.4%</font> to $21.40.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527934\" data-linked=\"Redfin gains as firm praises fee increase\" data-tweet=\"$RDFN - Redfin gains as firm praises fee increase https://seekingalpha.com/news/3527934-redfin-gains-firm-praises-fee-increase?source=tweet\" data-url=\"https://seekingalpha.com/news/3527934-redfin-gains-firm-praises-fee-increase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527928\" data-ts=\"1576872753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYB\" target=\"_blank\">LYB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527928-lyondellbasell-downgraded-rbc-on-propylene-price-weakness\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LyondellBasell downgraded at RBC on propylene price weakness</a></h4><ul><li>LyondellBasell (<a href='https://seekingalpha.com/symbol/LYB' title='LyondellBasell Industries N.V.'>LYB</a> <font color='red'>-1.7%</font>) is lower after RBC Capital <a href=\"https://thefly.com/thestreet/realmoney/index.php/LYBid3009657/LYB-RBC-downgrades-LyondellBasell-to-Sector-Perform-on-limited-positive-catalysts\" target=\"_blank\">downgrades</a> shares to Sector Perform from Outperform with a $95 price target, down from $102, seeing limited positive catalysts for the near  term as declining propylene prices impact metathesis conversion  margins.</li><li>Furthermore, the auto industry is \"weak,\" RBC analyst Arun Viswanathan says, adding his \"conservative view\" on weak monomer markets and a challenging margin environment in Europe suggest LYB shares may be fairly valued and could be  range-bound for 6-12 months.</li><li>LYB's average <a href=\"https://seekingalpha.com/symbol/LYB/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> and <a href=\"https://seekingalpha.com/symbol/LYB/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors Rating</a> are Bullish, while its <a href=\"https://seekingalpha.com/symbol/LYB/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527928\" data-linked=\"LyondellBasell downgraded at RBC on propylene price weakness\" data-tweet=\"$LYB - LyondellBasell downgraded at RBC on propylene price weakness https://seekingalpha.com/news/3527928-lyondellbasell-downgraded-rbc-on-propylene-price-weakness?source=tweet\" data-url=\"https://seekingalpha.com/news/3527928-lyondellbasell-downgraded-rbc-on-propylene-price-weakness\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527926\" data-ts=\"1576872286\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527926-10x-genomics-and-care-com-among-tech-gainers-calamp-and-technical-communications-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">10x Genomics and Care.com among Tech gainers; CalAmp and Technical Communications among losers</a></h4><ul><li><b>Gainers: </b>10x Genomics (NASDAQ:<a href='https://seekingalpha.com/symbol/TXG' title='10x Genomics, Inc.'>TXG</a>) <font color=\"green\">+20%</font>. Care.com (NYSE:<a href='https://seekingalpha.com/symbol/CRCM' title='Care.com, Inc.'>CRCM</a>) <font color=\"green\">+13%</font>. BlackBerry (NYSE:<a href='https://seekingalpha.com/symbol/BB' title='BlackBerry Limited'>BB</a>) <font color=\"green\">+12%</font>. Health Catalyst (NASDAQ:<a href='https://seekingalpha.com/symbol/HCAT' title='Health Catalyst, Inc.'>HCAT</a>) <font color=\"green\">+10%</font>. CLPS (NASDAQ:<a href='https://seekingalpha.com/symbol/CLPS' title='CLPS Incorporation'>CLPS</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>CalAmp (NASDAQ:<a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a>) <font color=\"red\">-17%</font>. Technical Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corporation'>TCCO</a>) <font color=\"red\">-15%</font>. Luokung Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/LKCO' title='Luokung Technology Corp.'>LKCO</a>) <font color=\"red\">-14%</font>. Jianpu Technology (NYSE:<a href='https://seekingalpha.com/symbol/JT' title='Jianpu Technology Inc.'>JT</a>) <font color=\"red\">-10%</font>. Fujian Blue Hat Interactive Entertainment Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/BHAT' title='Fujian Blue Hat Interactive Entertainment Technology Ltd.'>BHAT</a>) <font color=\"red\">-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527926\" data-linked=\"10x Genomics and Care.com among Tech gainers; CalAmp and Technical Communications among losers\" data-tweet=\"$TXG $CRCM $BB - 10x Genomics and Care.com among Tech gainers; CalAmp and Technical Communications among losers https://seekingalpha.com/news/3527926-10x-genomics-and-care-com-among-tech-gainers-calamp-and-technical-communications-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527926-10x-genomics-and-care-com-among-tech-gainers-calamp-and-technical-communications-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527912\" data-ts=\"1576868854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527912-lightbridge-and-trilogy-metals-among-energy-material-gainers-insteel-industries-and-united\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lightbridge and Trilogy Metals among Energy/Material gainers; Insteel Industries and United States Steel among losers</a></h4><ul><li><b>Gainers: </b>Lightbridge (NASDAQ:<a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corporation'>LTBR</a>) <font color=\"green\">+15%</font>. Trilogy Metals (NYSEMKT:<a href='https://seekingalpha.com/symbol/TMQ' title='Trilogy Metals Inc.'>TMQ</a>) <font color=\"green\">+9%</font>. Chaparral Energy (NYSE:<a href='https://seekingalpha.com/symbol/CHAP' title='Chaparral Energy, Inc.'>CHAP</a>) <font color=\"green\">+8%</font>. Mammoth Energy Services (NASDAQ:<a href='https://seekingalpha.com/symbol/TUSK' title='Mammoth Energy Services, Inc.'>TUSK</a>) <font color=\"green\">+7%</font>. Permianville Royalty Trust (NYSE:<a href='https://seekingalpha.com/symbol/PVL' title='Permianville Royalty Trust'>PVL</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Insteel Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/IIIN' title='Insteel Industries, Inc.'>IIIN</a>) <font color=\"red\">-11%</font>. United States Steel (NYSE:<a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a>) <font color=\"red\">-11%</font>. Contango Oil &amp; Gas (NYSEMKT:<a href='https://seekingalpha.com/symbol/MCF' title='Contango Oil & Gas Company'>MCF</a>) <font color=\"red\">-10%</font>. Pacific Drilling (NYSE:<a href='https://seekingalpha.com/symbol/PACD' title='Pacific Drilling S.A.'>PACD</a>) <font color=\"red\">-10%</font>. KLX Energy Services (NASDAQ:<a href='https://seekingalpha.com/symbol/KLXE' title='KLX Energy Services Holdings, Inc.'>KLXE</a>) <font color=\"red\">-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527912\" data-linked=\"Lightbridge and Trilogy Metals among Energy/Material gainers; Insteel Industries and United States Steel among losers\" data-tweet=\"$LTBR $TMQ $CHAP - Lightbridge and Trilogy Metals among Energy/Material gainers; Insteel Industries and United States Steel among losers https://seekingalpha.com/news/3527912-lightbridge-and-trilogy-metals-among-energy-material-gainers-insteel-industries-and-united?source=tweet\" data-url=\"https://seekingalpha.com/news/3527912-lightbridge-and-trilogy-metals-among-energy-material-gainers-insteel-industries-and-united\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527885\" data-ts=\"1576867375\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527885-nvidia-named-top-pick-target-raised-sharesplus-1_9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nvidia named top pick, target raised; shares +1.9%</a></h4><ul><li>Wells Fargo names Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) its top semiconductor pick for 2020 and raises the price target from $240 to $270.</li><li>Analyst Aaron Rakers says NVDA has the \"most significant investor sentiment upside\" and stands to benefit from next year's re-acceleration in data center spending.</li><li>Nvidia shares are <font color=\"green\">up 1.9%</font> to $239.90. The company has a Bullish average<a href=\"https://seekingalpha.com/symbol/NVDA/ratings/sell-side-ratings\" target=\"_blank\"> Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527885\" data-linked=\"Nvidia named top pick, target raised; shares +1.9%\" data-tweet=\"$NVDA - Nvidia named top pick, target raised; shares +1.9% https://seekingalpha.com/news/3527885-nvidia-named-top-pick-target-raised-sharesplus-1_9?source=tweet\" data-url=\"https://seekingalpha.com/news/3527885-nvidia-named-top-pick-target-raised-sharesplus-1_9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527877\" data-ts=\"1576866862\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527877-amd-target-boosted-on-potential-chip-gains-sharesplus-2_9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMD target boosted on potential chip gains; shares +2.9%</a></h4><ul><li>Wedbush analyst Matt Bryson raises his AMD (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) target from $39 to $51.50, citing positive Threadripper reviews that continue \"a theme of the CPU vendor supplying competitive, or even superior parts\" compared to Intel (<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a> <font color='green'>+1.3%</font>).</li><li>The analyst says the setup allows AMD to charge a premium, which lifts shares, revenue per part, and margin.</li><li>Wedbush maintains an Outperform rating on AMD. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/AMD/ratings/author-ratings#filter=all\" target=\"_blank\">SA Author's rating</a>.</li><li>AMD shares are <font color=\"green\">up 2.9%</font> to $44.05.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527877\" data-linked=\"AMD target boosted on potential chip gains; shares +2.9%\" data-tweet=\"$AMD $INTC - AMD target boosted on potential chip gains; shares +2.9% https://seekingalpha.com/news/3527877-amd-target-boosted-on-potential-chip-gains-sharesplus-2_9?source=tweet\" data-url=\"https://seekingalpha.com/news/3527877-amd-target-boosted-on-potential-chip-gains-sharesplus-2_9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>147&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527861\" data-ts=\"1576866166\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KEY\" target=\"_blank\">KEY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527861-wedbush-turns-bullish-on-keycorp-neutral-on-bok-finacial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wedbush turns bullish on KeyCorp, neutral on BOK Finacial</a></h4><ul><li>KeyCorp (NYSE:<a href='https://seekingalpha.com/symbol/KEY' title='KeyCorp'>KEY</a>) <font color=\"green\">gains 1.2%</font> after Wedbush analyst Peter Winter upgrades the bank to outperform from neutral on the view that it's positioned for above-average EPS growth.</li><li>BOK Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/BOKF' title='BOK Financial Corporation'>BOKF</a>) <font color=\"red\">slips 1.1% </font>after Winter cuts to neutral from outperform as Winter sees earnings challenges for the bank.</li><li>KeyCorp's margin is well-positioned for the current rate environment; it should see above-average loan growth with relatively stable expenses in 2020, Winter writes.</li><li>Sees 2020 EPS at $1.95 vs. $1.88 consensus.</li><li>Meanwhile, he sees BOK Financial as \"very asset sensitive\", while levers to offset pressure on net interest income are diminishing; the pace of its brokerage, trading, and mortgage banking growth is expected to slow next year.</li><li>Sees 2020 core EPS falling by 4%.</li><li>Looking at their Quant ratings, <a href=\"https://seekingalpha.com/symbol/KEY/ratings/quant-ratings?s=key\" target=\"_blank\">KeyCorp </a>and <a href=\"https://seekingalpha.com/symbol/BOKF/ratings/quant-ratings?s=bokf\" target=\"_blank\">BOK Financial </a>both rank Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527861\" data-linked=\"Wedbush turns bullish on KeyCorp, neutral on BOK Finacial\" data-tweet=\"$KEY $BOKF - Wedbush turns bullish on KeyCorp, neutral on BOK Finacial https://seekingalpha.com/news/3527861-wedbush-turns-bullish-on-keycorp-neutral-on-bok-finacial?source=tweet\" data-url=\"https://seekingalpha.com/news/3527861-wedbush-turns-bullish-on-keycorp-neutral-on-bok-finacial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527852\" data-ts=\"1576865500\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYRS\" target=\"_blank\">SYRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527852-syros-pharma-up-16-on-addition-of-former-celgene-chief-to-board\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Syros Pharma up 16% on addition of former Celgene chief to board</a></h4><ul><li>Syros Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals, Inc.'>SYRS</a> <font color=\"green\">+16.3%</font>) is up on a 10x surge on volume in apparent response to its <a href=\"https://seekingalpha.com/pr/17734341-syros-announces-appointment-of-mark-alles-to-board-of-directors\" target=\"_blank\">announcement </a>that former Celgene Chairman and CEO Mark Alles has joined the board.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527852\" data-linked=\"Syros Pharma up 16% on addition of former Celgene chief to board\" data-tweet=\"$SYRS - Syros Pharma up 16% on addition of former Celgene chief to board https://seekingalpha.com/news/3527852-syros-pharma-up-16-on-addition-of-former-celgene-chief-to-board?source=tweet\" data-url=\"https://seekingalpha.com/news/3527852-syros-pharma-up-16-on-addition-of-former-celgene-chief-to-board\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527849\" data-ts=\"1576865181\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527849-mack-cali-realty-and-bat-group-among-financial-gainers-first-guaranty-bancshares-and-carver\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mack-Cali Realty and Bat Group among Financial gainers; First Guaranty Bancshares and Carver Bancorp among losers</a></h4><ul><li><b>Gainers: </b>Mack-Cali Realty (NYSE:<a href='https://seekingalpha.com/symbol/CLI' title='Mack-Cali Realty Corporation'>CLI</a>) <font color=\"green\">+8%</font>. Bat Group (NASDAQ:<a href='https://seekingalpha.com/symbol/GLG' title='Bat Group, Inc.'>GLG</a>) <font color=\"green\">+7%</font>. Colliers International (NASDAQ:<a href='https://seekingalpha.com/symbol/CIGI' title='Colliers International Group Inc.'>CIGI</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>First Guaranty Bancshares (NASDAQ:<a href='https://seekingalpha.com/symbol/FGBI' title='First Guaranty Bancshares, Inc.'>FGBI</a>) <font color=\"red\">-6%</font>. Carver Bancorp (NASDAQ:<a href='https://seekingalpha.com/symbol/CARV' title='Carver Bancorp, Inc.'>CARV</a>) <font color=\"red\">-6%</font>. ATIF Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/ATIF' title='ATIF Holdings Limited'>ATIF</a>) <font color=\"red\">-6%</font>. Leaf Group (NYSE:<a href='https://seekingalpha.com/symbol/LEAF' title='Leaf Group Ltd.'>LEAF</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527849\" data-linked=\"Mack-Cali Realty and Bat Group among Financial gainers; First Guaranty Bancshares and Carver Bancorp among losers\" data-tweet=\"$CLI $GLG $CIGI - Mack-Cali Realty and Bat Group among Financial gainers; First Guaranty Bancshares and Carver Bancorp among losers https://seekingalpha.com/news/3527849-mack-cali-realty-and-bat-group-among-financial-gainers-first-guaranty-bancshares-and-carver?source=tweet\" data-url=\"https://seekingalpha.com/news/3527849-mack-cali-realty-and-bat-group-among-financial-gainers-first-guaranty-bancshares-and-carver\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527844\" data-ts=\"1576864754\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527844-aar-leads-industrial-gainers-shiloh-industries-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AAR leads industrial gainers; Shiloh Industries among losers</a></h4><ul><li><b>Gainers: </b>AAR (NYSE:<a href='https://seekingalpha.com/symbol/AIR' title='AAR Corp.'>AIR</a>) <font color=\"green\">+12%</font>. Perma-Pipe International (NASDAQ:<a href='https://seekingalpha.com/symbol/PPIH' title='Perma-Pipe International Holdings, Inc.'>PPIH</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Innovative Solutions and Support (NASDAQ:<a href='https://seekingalpha.com/symbol/ISSC' title='Innovative Solutions and Support, Inc.'>ISSC</a>) <font color=\"red\">-9%</font>. Shiloh Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/SHLO' title='Shiloh Industries, Inc.'>SHLO</a>) <font color=\"red\">-8%</font>. CUI Global (NASDAQ:<a href='https://seekingalpha.com/symbol/CUI' title='CUI Global, Inc.'>CUI</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527844\" data-linked=\"AAR leads industrial gainers; Shiloh Industries among losers\" data-tweet=\"$AIR $PPIH $ISSC - AAR leads industrial gainers; Shiloh Industries among losers https://seekingalpha.com/news/3527844-aar-leads-industrial-gainers-shiloh-industries-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527844-aar-leads-industrial-gainers-shiloh-industries-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527840\" data-ts=\"1576863500\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527840-rad-camp-abeo-and-mrns-in-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RAD, CAMP, ABEO and MRNS in midday movers</a></h4><ul><li><strong>Gainers: </strong>Marinus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals, Inc.'>MRNS</a>) <font color=\"green\">+42%</font>.</li><li>Prothena (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTA' title='Prothena Corporation plc'>PRTA</a>) <font color=\"green\">+27%</font>.</li><li>Applied Genetic Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AGTC' title='Applied Genetic Technologies Corporation'>AGTC</a>) <font color=\"green\">+26%</font>.</li><li>Rite Aid (NYSE:<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) <font color=\"green\">+25%</font>.</li><li>Ruhnn Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/RUHN' title='Ruhnn Holding Limited'>RUHN</a>) <font color=\"green\">+20%</font>.</li><li>Cortexyme (NASDAQ:<a href='https://seekingalpha.com/symbol/CRTX' title='Cortexyme, Inc.'>CRTX</a>) <font color=\"green\">+20%</font>.</li><li>10x Genomics (NASDAQ:<a href='https://seekingalpha.com/symbol/TXG' title='10x Genomics, Inc.'>TXG</a>) <font color=\"green\">+19%</font></li><li>Cabaletta Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/CABA' title='Cabaletta Bio, Inc.'>CABA</a>) <font color=\"green\">+19%</font>.</li><li>LAIX (NYSE:<a href='https://seekingalpha.com/symbol/LAIX' title='LAIX Inc.'>LAIX</a>) <font color=\"green\">+18%</font>.</li><li>Cassava Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SAVA' title='Cassava Sciences, Inc.'>SAVA</a>) <font color=\"green\">+18%</font>.</li><li><strong>Losers: </strong>Stealth BioTherapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MITO' title='Stealth BioTherapeutics Corp'>MITO</a>) <font color=\"red\">-63%</font>.</li><li>Valeritas Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a>) <font color=\"red\">-54%</font>.</li><li>Abeona Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a>) <font color=\"red\">-37%</font>.</li><li>Nabriva Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics plc'>NBRV</a>) <font color=\"red\">-20%</font>.</li><li>CalAmp (NASDAQ:<a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a>) <font color=\"red\">-17%</font>.</li><li>Vaccinex (NASDAQ:<a href='https://seekingalpha.com/symbol/VCNX' title='Vaccinex, Inc.'>VCNX</a>) <font color=\"red\">-13%</font>.</li><li>ENDRA Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NDRA' title='ENDRA Life Sciences Inc.'>NDRA</a>) <font color=\"red\">-12%</font>.</li><li>Health Insurance Innovations (NASDAQ:<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations, Inc.'>HIIQ</a>) <font color=\"red\">-12%</font>.</li><li>Trans World Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/TWMC' title='Trans World Entertainment Corporation'>TWMC</a>) <font color=\"red\">-11%</font>.</li><li>Dicerna Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a>) <font color=\"red\">-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527840\" data-linked=\"RAD, CAMP, ABEO and MRNS in midday movers\" data-tweet=\"$MRNS $PRTA $AGTC - RAD, CAMP, ABEO and MRNS in midday movers https://seekingalpha.com/news/3527840-rad-camp-abeo-and-mrns-in-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527840-rad-camp-abeo-and-mrns-in-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527819\" data-ts=\"1576861748\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVRA\" target=\"_blank\">SVRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527819-savara-secures-26_8m-capital-raise-shares-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Savara secures $26.8M capital raise; shares up 5%</a></h4><ul><li>Nano cap Savara (<a href='https://seekingalpha.com/symbol/SVRA' title='Savara Inc.'>SVRA</a> <font color=\"green\">+4.7%</font>) is up, albeit on below-average volume, on the heels of its <a href=\"https://seekingalpha.com/pr/17734742-savara-announces-private-placement-of-26_8-million-total-potential-proceeds-of-75_0-million\" target=\"_blank\">private capital raise</a> with institutional investors.</li><li>It has agreed to sell ~9.6M common shares (or pre-funded warrants to purchase up to ~5.8M common shares at $1.479) plus two-year warrants to purchase up to ~32.6M common shares at $1.48 at a combined price of $1.745 (or $1.744 per pre-funded warrant + two-year warrant).</li><li>Net proceeds will fund a new clinical trial of evaluating lead drug <a href=\"https://savarapharma.com/development/programs/\" target=\"_blank\">Molgradex</a> in patients with autoimmune pulmonary alveolar proteinosis and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527819\" data-linked=\"Savara secures $26.8M capital raise; shares up 5%\" data-tweet=\"$SVRA - Savara secures $26.8M capital raise; shares up 5% https://seekingalpha.com/news/3527819-savara-secures-26_8m-capital-raise-shares-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3527819-savara-secures-26_8m-capital-raise-shares-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527818\" data-ts=\"1576861289\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527818-winnebago-industries-among-consumer-gainers-adient-and-peloton-interactive-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Winnebago Industries among consumer gainers; Adient and Peloton Interactive among losers</a></h4><ul><li><b>Gainers: </b>Mohawk Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MWK' title='Mohawk Group Holdings, Inc.'>MWK</a>) <font color=\"green\">+15%</font>. TDH Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/PETZ' title='TDH Holdings, Inc.'>PETZ</a>) <font color=\"green\">+14%</font>. The Alkaline Water Company (NASDAQ:<a href='https://seekingalpha.com/symbol/WTER' title='The Alkaline Water Company Inc.'>WTER</a>) <font color=\"green\">+11%</font>. Winnebago Industries (NYSE:<a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a>) <font color=\"green\">+9%</font>. Primo Water (NASDAQ:<a href='https://seekingalpha.com/symbol/PRMW' title='Primo Water Corporation'>PRMW</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Eastside Distilling (NASDAQ:<a href='https://seekingalpha.com/symbol/EAST' title='Eastside Distilling, Inc.'>EAST</a>) <font color=\"red\">-6%</font>. Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp.'>SOLO</a>) <font color=\"red\">-6%</font>. Peloton Interactive (NASDAQ:<a href='https://seekingalpha.com/symbol/PTON' title='Peloton Interactive, Inc.'>PTON</a>) <font color=\"red\">-6%</font>. Adient (NYSE:<a href='https://seekingalpha.com/symbol/ADNT' title='Adient plc'>ADNT</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527818\" data-linked=\"Winnebago Industries among consumer gainers; Adient and Peloton Interactive among losers\" data-tweet=\"$MWK $PETZ $WTER - Winnebago Industries among consumer gainers; Adient and Peloton Interactive among losers https://seekingalpha.com/news/3527818-winnebago-industries-among-consumer-gainers-adient-and-peloton-interactive-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527818-winnebago-industries-among-consumer-gainers-adient-and-peloton-interactive-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527800\" data-ts=\"1576858433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCHL\" target=\"_blank\">SCHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527800-scholasticplus-7-after-earnings-impress\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scholastic +7% after earnings impress</a></h4><ul> <li>Scholastic Corporation (<a href='https://seekingalpha.com/symbol/SCHL' title='Scholastic Corporation'>SCHL</a> <font color='green'>+6.2%</font>) rallies after blasting past <a href=\"https://seekingalpha.com/pr/17733810-scholastic-reports-fiscal-2020-second-quarter-results\" target=\"_blank\">FQ2</a> estimates.</li> <li>Trade revenues rose 8% during the quarter and operating income rose 7% amid improvements in the company's book fairs operations, better cost management in clubs and lower technology-related overhead expense.</li> <li>Looking ahead, Scholastic sees FY20 revenue of $1.67B to $1.70B vs. $1.69B consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527542-scholastic-eps-beats-0_25-beats-on-revenue\" target=\"_blank\">Scholastic EPS beats by $0.25, beats on revenue</a> (Dec. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527800\" data-linked=\"Scholastic +7% after earnings impress\" data-tweet=\"$SCHL - Scholastic +7% after earnings impress https://seekingalpha.com/news/3527800-scholasticplus-7-after-earnings-impress?source=tweet\" data-url=\"https://seekingalpha.com/news/3527800-scholasticplus-7-after-earnings-impress\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527794\" data-ts=\"1576857707\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARAV\" target=\"_blank\">ARAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527794-aravive-launches-mid-stage-study-of-avbminus-500-in-kidney-disorder\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aravive launches mid-stage study of AVB-500 in kidney disorder</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17734358-aravive-initiates-phase-2a-clinical-trial-of-avbminus-500-in-patients-kidney-fibrosis\" target=\"_blank\">Enrollment is underway</a> in a <a href=\"https://clinicaltrials.gov/ct2/show/NCT04042623?term=NCT04042623&amp;draw=2&amp;rank=1\" target=\"_blank\">Phase 2 clinical trial</a> evaluating Aravive's (<a href='https://seekingalpha.com/symbol/ARAV' title='Aravive, Inc.'>ARAV</a> <font color=\"red\">-2.6%</font>) lead candidate AVB-500 in patients with <a href=\"https://www.mayoclinic.org/diseases-conditions/iga-nephropathy/symptoms-causes/syc-20352268\" target=\"_blank\">IgA nephropathy</a>, also known as Berger's disease, characterized by the gradual buildup of immunoglobulin A (IgA) in the kidneys which leads to inflammation and comprised organ function.</li><li>Primary endpoints of the 24-subject study include safety and a range of efficacy measures. The estimated primary completion date is December 2020.</li><li>The company says <a href=\"https://aravive.com/pipeline/\" target=\"_blank\">AVB-500</a> is an ultra-high affinity decoy protein that suppresses fibrosis (scarring) and cancer cell proliferation by capturing and binding to a protein called GAS6, overexpressed in Berger's disease and ovarian cancer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527794\" data-linked=\"Aravive launches mid-stage study of AVB-500 in kidney disorder\" data-tweet=\"$ARAV - Aravive launches mid-stage study of AVB-500 in kidney disorder https://seekingalpha.com/news/3527794-aravive-launches-mid-stage-study-of-avbminus-500-in-kidney-disorder?source=tweet\" data-url=\"https://seekingalpha.com/news/3527794-aravive-launches-mid-stage-study-of-avbminus-500-in-kidney-disorder\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527792\" data-ts=\"1576857650\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527792-marinus-pharmaceuticals-leads-healthcare-gainers-abeona-therapeutics-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marinus Pharmaceuticals leads healthcare gainers; Abeona Therapeutics among losers</a></h4><ul><li><b>Gainers: </b>Marinus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals, Inc.'>MRNS</a>) <font color=\"green\">+35%</font>. Applied Genetic Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AGTC' title='Applied Genetic Technologies Corporation'>AGTC</a>) <font color=\"green\">+28%</font>. NewLink Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a>) <font color=\"green\">+24%</font>. Artelo Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ARTL' title='Artelo Biosciences, Inc.'>ARTL</a>) <font color=\"green\">+20%</font>. Syros Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SYRS' title='Syros Pharmaceuticals, Inc.'>SYRS</a>) <font color=\"green\">+16%</font>.</li><li><b>Losers: </b>Stealth BioTherapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MITO' title='Stealth BioTherapeutics Corp'>MITO</a>) <font color=\"red\">-64%</font>. Valeritas Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a>) <font color=\"red\">-53%</font>. Abeona Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a>) <font color=\"red\">-34%</font>. Nabriva Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics plc'>NBRV</a>) <font color=\"red\">-20%</font>. Health Insurance Innovations (NASDAQ:<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations, Inc.'>HIIQ</a>) <font color=\"red\">-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527792\" data-linked=\"Marinus Pharmaceuticals leads healthcare gainers; Abeona Therapeutics among losers\" data-tweet=\"$MRNS $AGTC $NLNK - Marinus Pharmaceuticals leads healthcare gainers; Abeona Therapeutics among losers https://seekingalpha.com/news/3527792-marinus-pharmaceuticals-leads-healthcare-gainers-abeona-therapeutics-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527792-marinus-pharmaceuticals-leads-healthcare-gainers-abeona-therapeutics-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527790\" data-ts=\"1576857128\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BA\" target=\"_blank\">BA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527790-boeing-starliner-will-not-reach-space-station-after-test-failure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boeing Starliner will not reach space station after test failure</a></h4><ul><li>Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color='red'>-1.4%</font>) slips to its lowest levels of the day on news that its Starliner space capsule <a href=\"https://www.cnbc.com/2019/12/20/boeings-starliner-flies-into-wrong-orbit-jeopardizing-trip-to-the-international-space-station.html\" target=\"_blank\">will not dock</a> with the International Space Station as planned after <a href=\"https://seekingalpha.com/news/3527729-boeing-starliner-fails-to-reach-correct-orbit-in-key-test\" target=\"_blank\">failing to reach the correct orbit</a> during a key flight test mission.</li><li>Because of a <a href=\"https://www.reuters.com/article/us-space-exploration-boeing/timer-error-thwarts-boeings-test-capsule-mission-to-space-station-idUSKBN1YO1A7\" target=\"_blank\">timer error</a>, the spacecraft \"believed it was in an orbital insertion burn\" and \"burned more fuel than anticipated to maintain precise control,\" which will prevent a rendezvous with the space station, NASA Administration Jim Bridenstine says.</li><li>NASA and Boeing still hope to salvage some of the test mission if possible, as Bridenstine said \"we are getting good burns and are elevating the orbit of the spacecraft.\"</li><li>\"The challenge here has to do with automation,\" Bridenstine said of the unmanned spacecraft, adding that if astronauts had been on board they would have been able to override the automated system that caused the error.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527790\" data-linked=\"Boeing Starliner will not reach space station after test failure\" data-tweet=\"$BA - Boeing Starliner will not reach space station after test failure https://seekingalpha.com/news/3527790-boeing-starliner-will-not-reach-space-station-after-test-failure?source=tweet\" data-url=\"https://seekingalpha.com/news/3527790-boeing-starliner-will-not-reach-space-station-after-test-failure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527789\" data-ts=\"1576856867\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527789-cruise-line-stocks-follow-carnival-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cruise line stocks follow Carnival higher</a></h4><ul> <li>Royal Caribbean (<a href='https://seekingalpha.com/symbol/RCL' title='Royal Caribbean Cruises Ltd.'>RCL</a> <font color='green'>+3.6%</font>) and Norwegian Cruise Line Holdings (<a href='https://seekingalpha.com/symbol/NCLH' title='Norwegian Cruise Line Holdings Ltd.'>NCLH</a> <font color='green'>+4.3%</font>) jump after Carnival easily tops estimates with its FQ4 report.</li> <li>Carnival also set profit guidance ahead of expectations for the quarter ahead that includes the important Wave Season.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3527786-carnivalplus-9-after-earnings-smasher\" target=\"_blank\">Carnival +9% after earnings smasher</a> (Dec. 20)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527789\" data-linked=\"Cruise line stocks follow Carnival higher\" data-tweet=\"$RCL $NCLH - Cruise line stocks follow Carnival higher https://seekingalpha.com/news/3527789-cruise-line-stocks-follow-carnival-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3527789-cruise-line-stocks-follow-carnival-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527786\" data-ts=\"1576856637\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCL\" target=\"_blank\">CCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527786-carnivalplus-9-after-earnings-smasher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Carnival +9% after earnings smasher</a></h4><ul> <li>Carnival (<a href='https://seekingalpha.com/symbol/CCL' title='Carnival Corporation & Plc'>CCL</a> <font color='green'>+9.2%</font>) rallies after easily topping estimates with its <a href=\"https://seekingalpha.com/pr/17734562-carnival-corporation-plc-reports-fourth-quarter-and-full-year-earnings\" target=\"_blank\">FQ4</a> report.</li> <li>The cruise line operator reports net revenue yields fell 3.6% during the quarter vs. -3.9% consensus. Net cruise costs were up 1.0% after factoring out fuel vs. +3.0% consensus. The company says it had to overcome a high number of unusual events during the quarter, compounded by a significant downturn in leisure travel demand for large source markets in Continental Europe.</li> <li>Looking ahead, Carnival sees FQ1 EPS of $0.47 to $0.50 vs. $0.40 consensus off net cruise revenue growth of 4.0%.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3527749-carnival-eps-beats-0_11-beats-on-revenue\" target=\"_blank\">Carnival EPS beats by $0.11, beats on revenue</a> (Dec. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3527786\" data-linked=\"Carnival +9% after earnings smasher\" data-tweet=\"$CCL - Carnival +9% after earnings smasher https://seekingalpha.com/news/3527786-carnivalplus-9-after-earnings-smasher?source=tweet\" data-url=\"https://seekingalpha.com/news/3527786-carnivalplus-9-after-earnings-smasher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527785\" data-ts=\"1576856467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLNK\" target=\"_blank\">NLNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527785-newlink-genetics-up-33-on-fda-nod-for-merck-ebola-vaccine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NewLink Genetics up 33% on FDA nod for Merck Ebola vaccine</a></h4><ul><li>NewLink Genetics (<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color=\"green\">+32.9%</font>) is up on more than an 8x surge in volume in response to the <a href=\"https://seekingalpha.com/news/3527618-fda-oks-merck-ebola-vaccine\" target=\"_blank\">FDA's approval</a> of Merck's Ebola vaccine Ervebo.</li><li>The company out-licensed the rights to the vaccine, known as rVSV-ZEBOV at the time, to Merck in 2014.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527785\" data-linked=\"NewLink Genetics up 33% on FDA nod for Merck Ebola vaccine\" data-tweet=\"$NLNK - NewLink Genetics up 33% on FDA nod for Merck Ebola vaccine https://seekingalpha.com/news/3527785-newlink-genetics-up-33-on-fda-nod-for-merck-ebola-vaccine?source=tweet\" data-url=\"https://seekingalpha.com/news/3527785-newlink-genetics-up-33-on-fda-nod-for-merck-ebola-vaccine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527781\" data-ts=\"1576855787\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLO\" target=\"_blank\">SHLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527781-shiloh-industries-slips-8-on-q4-results-miss-provides-fy20-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shiloh Industries slips 8% on Q4 results miss; provides FY20 guidance</a></h4><ul><li>Shiloh Industries (<a href='https://seekingalpha.com/symbol/SHLO' title='Shiloh Industries, Inc.'>SHLO</a> <font color=\"red\">-8.4%</font>) reported Q4 revenue decline of 13.7% Y/Y to $258.96M; and net loss of $13.7M, compared to $8.46M a year ago.</li><li>Q4 Gross margin<font color=\"green\"> improved by 157 bps</font> to 9.5%; and Adj. operating margin <font color=\"green\">improved by 130 bps</font> to 1.5%.</li><li>Adj. EBITDA was $16.61M (+10.9% Y/Y); and margin <font color=\"green\">improved by 145 bps</font> to 6.4%.</li><li>Net cash provided by operating activities for FY19 was $31.25M, compared to $53.23M a year ago.</li><li><strong>FY20 Outlook: </strong>Revenue of ~$1B, and adj. EBITDA in the range of $75M to $80M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527556-shiloh-eps-misses-0_02-misses-on-revenue\" target=\"_blank\">Shiloh EPS misses by $0.02, misses on revenue</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3527781\" data-linked=\"Shiloh Industries slips 8% on Q4 results miss; provides FY20 guidance\" data-tweet=\"$SHLO - Shiloh Industries slips 8% on Q4 results miss; provides FY20 guidance https://seekingalpha.com/news/3527781-shiloh-industries-slips-8-on-q4-results-miss-provides-fy20-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3527781-shiloh-industries-slips-8-on-q4-results-miss-provides-fy20-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527779\" data-ts=\"1576855623\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIIQ\" target=\"_blank\">HIIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527779-health-insurance-innovations-down-14-on-shift-to-medicare-segment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Health Insurance Innovations down 14% on shift to Medicare segment</a></h4><ul><li>Health Insurance Innovations (<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations, Inc.'>HIIQ</a> <font color=\"red\">-13.6%</font>) is down on modestly higher volume on the heels of its <a href=\"https://seekingalpha.com/pr/17734542-health-insurance-innovations-inc-provides-update-on-business-strategy-and-ongoing-strategic\" target=\"_blank\">strategy update</a>. CEO Gavin Southwell says the company will prioritize its buildout into the Medicare space, but cautions that the shift may lead to the exit of \"certain carrier and distribution relationships\" in the individual and family plan &#40;IFP&#41; arena.</li><li>In the meantime, the company will focus on maximizing cash flows in the IFP business while enhancing its e-commerce capabilities. Mr. Southwell expects its existing IFP book to generate ~$170M in net cash flow, mostly in 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527779\" data-linked=\"Health Insurance Innovations down 14% on shift to Medicare segment\" data-tweet=\"$HIIQ - Health Insurance Innovations down 14% on shift to Medicare segment https://seekingalpha.com/news/3527779-health-insurance-innovations-down-14-on-shift-to-medicare-segment?source=tweet\" data-url=\"https://seekingalpha.com/news/3527779-health-insurance-innovations-down-14-on-shift-to-medicare-segment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527777\" data-ts=\"1576855138\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527777-blackberry-guides-upside-fy20-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackBerry guides upside FY20 earnings</a></h4><ul><li>On the earnings call, BlackBerry (NYSE:<a href='https://seekingalpha.com/symbol/BB' title='BlackBerry Limited'>BB</a>) guides FY20 revenue of $1.1B, a growth of 20.2% versus the prior guidance of 23-25%. The company expects $0.08 EPS, above the $0.06 consensus.</li><li>RBC (Sector Perform, $7.50) calls the <a href=\"https://seekingalpha.com/news/3527688-blackberryplus-5_7-after-q3-beats\" target=\"_blank\">quarterly results</a> better than expected, but says the BlackBerry \"still faces challenges.\"</li><li>Raymond James (Market Perform) notes that growth in Enterprise Software and Services appears to have dropped Y/Y but increased sequentially. Licensing showed a small upside to the firm's expectations.</li><li>BlackBerry shares are <font color=\"green\">up 8.6%</font> to $6.30.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527777\" data-linked=\"BlackBerry guides upside FY20 earnings\" data-tweet=\"$BB - BlackBerry guides upside FY20 earnings https://seekingalpha.com/news/3527777-blackberry-guides-upside-fy20-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3527777-blackberry-guides-upside-fy20-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527776\" data-ts=\"1576854624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBRV\" target=\"_blank\">NBRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527776-nabriva-down-20-on-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nabriva down 20% on equity offering</a></h4><ul><li>Nabriva Therapeutics (<a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics plc'>NBRV</a> <font color=\"red\">-20.3%</font>) is down on more than triple normal volume in reaction to its <a href=\"https://seekingalpha.com/pr/17734462-nabriva-therapeutics-announces-20-million-registered-direct-offering\" target=\"_blank\">direct offering</a> of ~13.8M common shares and three-year warrants to purchase up to the same number of shares at $1.90 at a combined price of $1.45.</li><li>Yesterday's close was $1.72.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527776\" data-linked=\"Nabriva down 20% on equity offering\" data-tweet=\"$NBRV - Nabriva down 20% on equity offering https://seekingalpha.com/news/3527776-nabriva-down-20-on-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3527776-nabriva-down-20-on-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527774\" data-ts=\"1576854363\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527774-foot-locker-and-dicks-booted-lower-nike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Foot Locker and Dick&#39;s booted lower by Nike</a></h4><ul> <li>Foot Locker (<a href='https://seekingalpha.com/symbol/FL' title='Foot Locker, Inc.'>FL</a> <font color=\"red\">-1.5%</font>) and Dick's Sporting Goods (<a href='https://seekingalpha.com/symbol/DKS' title='Dick&#39;s Sporting Goods, Inc.'>DKS</a> <font color=\"red\">-1%</font>) are lower after Nike's earnings report underwhelms investors.</li> <li>The drop in Nike was tied to a slight margin miss and came on the heels of Nike shooting to an all-time high just before the report posted. Some analysts are calling the downward move in Foot Locker and Dick's an overreaction, with much of the underlying Nike sales numbers strong.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3527566-nike-falls-back-from-all-time-high\" target=\"_blank\">Nike falls back from all-time high</a> (Dec. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527774\" data-linked=\"Foot Locker and Dick&#39;s booted lower by Nike\" data-tweet=\"$FL $DKS - Foot Locker and Dick&#39;s booted lower by Nike https://seekingalpha.com/news/3527774-foot-locker-and-dicks-booted-lower-nike?source=tweet\" data-url=\"https://seekingalpha.com/news/3527774-foot-locker-and-dicks-booted-lower-nike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527775\" data-ts=\"1576854356\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCF\" target=\"_blank\">MCF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527775-contango-oil-to-sell-19m-shares-toward-juneau-development-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Contango Oil to sell 19M shares toward Juneau development deal</a></h4><ul><li>Contango Oil &amp; Gas (<a href='https://seekingalpha.com/symbol/MCF' title='Contango Oil & Gas Company'>MCF</a> <font color=\"red\">-21.9%</font>) plunges at the open on news that a group of institutional and accredited investors, led by certain funds and accounts advised by T. Rowe Price, plans to <a href=\"https://seekingalpha.com/pr/17734543-contango-announces-private-equity-capital-raise\" target=\"_blank\">sell 19M common shares</a> in a private placement.</li><li>MCF expects to receive more than $53M in gross proceeds from the equity capital raise, which it plans to use for capital spending under a new <a href=\"https://seekingalpha.com/pr/17734539-contango-oil-and-gas-company-announces-signing-of-joint-development-agreement-juneau-oil-gas\" target=\"_blank\">joint development agreement</a> with Juneau Oil &amp; Gas.</li><li>As part of the deal, MCF says it will acquire 85%-90% of Juneau's working interest in the Iron Flea prospect in the Gulf of Mexico; it expects $6.3M in dry hole costs for the exploration well after project payout.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527775\" data-linked=\"Contango Oil to sell 19M shares toward Juneau development deal\" data-tweet=\"$MCF - Contango Oil to sell 19M shares toward Juneau development deal https://seekingalpha.com/news/3527775-contango-oil-to-sell-19m-shares-toward-juneau-development-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3527775-contango-oil-to-sell-19m-shares-toward-juneau-development-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527769\" data-ts=\"1576853906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VLRX\" target=\"_blank\">VLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527769-valeritas-down-51-on-guidance-cut-due-to-v-go-supply-problem\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeritas down 51% on guidance cut due to V-Go supply problem</a></h4><ul><li>Thinly traded nano cap Valeritas Holdings (<a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a> <font color=\"red\">-51.2%</font>) slumps on almost a 5x surge in volume, albeit on turnover of only 674K shares, in response to its <a href=\"https://seekingalpha.com/pr/17734473-valeritas-experiences-temporary-supply-disruption-resulting-in-revised-preliminary-financial\" target=\"_blank\">revenue guidance cut</a> due to a manufacturing issue that caused a temporary disruption in product supply.</li><li>It expects to incur a temporary reduction in yields and will write off up to $8M in inventory. Gross margin this quarter will be negative.</li><li>Q4 revenue is now expected to be $8.0M - 8.2M. The topline for 2019 has been trimmed to $30.2M - 30.4M from $31.5M - 31.8M.</li><li>In other negative news, partner MedTrust has terminated its V-Go distribution agreement covering four countries due to pricing pressures in Germany and Austria. Valeritas has terminated its distribution deal with Julphar due to competitive pressures in the Middle East.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527769\" data-linked=\"Valeritas down 51% on guidance cut due to V-Go supply problem\" data-tweet=\"$VLRX - Valeritas down 51% on guidance cut due to V-Go supply problem https://seekingalpha.com/news/3527769-valeritas-down-51-on-guidance-cut-due-to-v-go-supply-problem?source=tweet\" data-url=\"https://seekingalpha.com/news/3527769-valeritas-down-51-on-guidance-cut-due-to-v-go-supply-problem\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527763\" data-ts=\"1576852908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABEO\" target=\"_blank\">ABEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527763-abeona-down-39-after-pricing-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abeona down 39% after pricing equity offering</a></h4><ul><li>Abeona Therapeutics (<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color=\"red\">-39.4%</font>) is down out the gate on a 5x surge in volume in reaction to its public offering of ~27M common shares at $2.50 per share or pre-funded warrants at $2.4999 per warrant. Gross proceeds should be $90M.</li><li>Underwriters' over-allotment is an additional 5.4M shares. Closing date is December 24.</li><li>Yesterday's close was $5.00.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527763\" data-linked=\"Abeona down 39% after pricing equity offering\" data-tweet=\"$ABEO - Abeona down 39% after pricing equity offering https://seekingalpha.com/news/3527763-abeona-down-39-after-pricing-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3527763-abeona-down-39-after-pricing-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527764\" data-ts=\"1576852908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/X\" target=\"_blank\">X</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527764-steel-peers-mixed-after-u-s-steel-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steel peers mixed after U.S. Steel warning</a></h4><ul><li>U.S. Steel (NYSE:<a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a>) late last night came out with a Q4 profit warning, and slashed its dividend to a penny from a nickel. Shares are<font color=\"red\"> off 9% </font>in early action.</li><li>Other players: Nucor (<a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a> <font color=\"red\">-0.1%</font>), AK Steel (<a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corporation'>AKS</a> <font color=\"red\">-2%</font>), Steel Dynamics (<a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a> <font color=\"green\">+0.2%</font>)</li><li>Sell-siders believe X's idling of its Great Lakes Works mill will generally be positive for supply-demand balance, and could benefit peers.</li><li>VanEck Steel ETF (<a href='https://seekingalpha.com/symbol/SLX' title='VanEck Vectors Steel ETF'>SLX</a>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527685-u-s-steelminus-8-on-q4-loss-and-cut-in-dividend\" target=\"_blank\">U.S. Steel -8% on Q4 loss and cut in dividend</a> (Dec. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3527764\" data-linked=\"Steel peers mixed after U.S. Steel warning\" data-tweet=\"$X $NUE $AKS - Steel peers mixed after U.S. Steel warning https://seekingalpha.com/news/3527764-steel-peers-mixed-after-u-s-steel-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3527764-steel-peers-mixed-after-u-s-steel-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527753\" data-ts=\"1576851903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DNKN\" target=\"_blank\">DNKN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527753-dunkin-brands-gains-on-guggenheim-confidence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dunkin&#39; Brands gains on Guggenheim confidence</a></h4><ul> <li>Dunkin' Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/DNKN' title='Dunkin&#39; Brands Group, Inc.'>DNKN</a>) breaks higher in early trading after Guggenheim lifts the restaurant stock to a Buy rating from Neutral.</li> <li>Analyst Matthew DiFrisco expects same-restaurant sales at the Dunkin' Donuts to chain to approach 3% this quarter, which would mark the highest level in six years. For 2020, he sees SRS staying above 2%.</li> <li>DiFrisco also notes that DNKN shares are trading at a discount to the average peer multiple.</li> <li>Looking further ahead, Dunkin' is seen moving forward with some \"NextGen\" attributes to build on the iced beverage momentum and a bartender culture.</li> <li>Guggenheim's price target of $83 is 18.5X the 2020 EBITDA estimate and stands clear of the <a href=\"https://seekingalpha.com/symbol/DNKN/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> of $80.48.</li> <li>Shares on DNKN are <font color=\"green\">up 1.44%</font> premarket to $74.60.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527753\" data-linked=\"Dunkin&#39; Brands gains on Guggenheim confidence\" data-tweet=\"$DNKN - Dunkin&#39; Brands gains on Guggenheim confidence https://seekingalpha.com/news/3527753-dunkin-brands-gains-on-guggenheim-confidence?source=tweet\" data-url=\"https://seekingalpha.com/news/3527753-dunkin-brands-gains-on-guggenheim-confidence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527751\" data-ts=\"1576851690\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527751-bb-wgo-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BB, WGO among premarket gainers</a></h4><ul><li>TRACON Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TCON' title='TRACON Pharmaceuticals, Inc.'>TCON</a>) <font color=\"green\">+25%</font> on <a href=\"https://seekingalpha.com/news/3527714-tracon-pharma-up-39-premarket-on-envafolimab-deal\" target=\"_blank\">envafolimab deal</a>.</li><li>Care.com (NYSE:<a href='https://seekingalpha.com/symbol/CRCM' title='Care.com, Inc.'>CRCM</a>) <font color=\"green\">+13%</font> on <a href=\"https://seekingalpha.com/news/3527738-iac-acquiring-care-com-for-500m-crcmplus-13_5\" target=\"_blank\">IAC acquisition</a>.</li><li>Marinus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals, Inc.'>MRNS</a>) <font color=\"green\">+12%</font>.</li><li>BlackBerry (NYSE:<a href='https://seekingalpha.com/symbol/BB' title='BlackBerry Limited'>BB</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/news/3527683-blackberry-eps-beats-0_01-beats-on-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Revolve Group (NYSE:<a href='https://seekingalpha.com/symbol/RVLV' title='Revolve Group, Inc.'>RVLV</a>) <font color=\"green\">+6%</font>.</li><li>ImmunoGen (NASDAQ:<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a>) <font color=\"green\">+5%</font>.</li><li>Winnebago Industries (NYSE:<a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a>) <font color=\"green\">+5%</font>. <a href=\"https://seekingalpha.com/news/3527682-winnebago-eps-beats-0_14-beats-on-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li>Cassava Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SAVA' title='Cassava Sciences, Inc.'>SAVA</a>) <font color=\"green\">+5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527751\" data-linked=\"BB, WGO among premarket gainers\" data-tweet=\"$TCON $CRCM $MRNS - BB, WGO among premarket gainers https://seekingalpha.com/news/3527751-bb-wgo-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527751-bb-wgo-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527750\" data-ts=\"1576851648\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXGT\" target=\"_blank\">AXGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527750-axovant-up-17-premarket-on-gene-therapy-data-in-rare-nerve-cell-disease\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axovant up 17% premarket on gene therapy data in rare nerve cell disease</a></h4><ul><li>Thinly traded micro cap Axovant Gene Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/AXGT' title='Axovant Gene Therapies Ltd.'>AXGT</a>) is up <font color=\"green\">17%</font> premarket on light volume in reaction to <a href=\"https://seekingalpha.com/pr/17734073-axovant-provides-clinical-program-update-for-axo-aav-gm1-novel-investigational-gene-therapy\" target=\"_blank\">results </a>from one child with GM1 gangliosidosis who received gene therapy candidate AXO-AAV-GM1.</li><li>At month 6 post-infusion, the patient showed clinically significant improvements on neurological exam, the Vineland-3 scale (used to assess intellectual and developmental disabilities), Clinical Global Impression &#40;CGI&#41; assessments and nutritional status.</li><li>The gene therapy was generally well-tolerated with no serious adverse events observed.</li><li>A registrational study is being conducted at NIH in collaboration with Axovant.</li><li><a href=\"https://ghr.nlm.nih.gov/condition/gm1-gangliosidosis\" target=\"_blank\">GM1 gangliosidosis</a> is a rare inherited lysosomal storage disorder caused by mutations in the GLB1 gene which leads to impaired production of an enzyme that plays an essential role in the breakdown of sugar molecules. The condition, which typically presents in infants, gradually destroys nerve cells in the brain and spinal cord.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527750\" data-linked=\"Axovant up 17% premarket on gene therapy data in rare nerve cell disease\" data-tweet=\"$AXGT - Axovant up 17% premarket on gene therapy data in rare nerve cell disease https://seekingalpha.com/news/3527750-axovant-up-17-premarket-on-gene-therapy-data-in-rare-nerve-cell-disease?source=tweet\" data-url=\"https://seekingalpha.com/news/3527750-axovant-up-17-premarket-on-gene-therapy-data-in-rare-nerve-cell-disease\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527749\" data-ts=\"1576851552\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCL\" target=\"_blank\">CCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527749-carnival-eps-beats-0_11-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Carnival EPS beats by $0.11, beats on revenue</a></h4><ul><li>Carnival (NYSE:<a href='https://seekingalpha.com/symbol/CCL' title='Carnival Corporation & Plc'>CCL</a>): Q4 Non-GAAP EPS of $0.62 <font color=\"green\">beats by $0.11</font>; GAAP EPS of $0.61 <font color=\"green\">beats by $0.10</font>.</li><li>Revenue of $4.78B (+7.2% Y/Y) <font color=\"green\">beats by $220M</font>.</li><li>Shares <font color=\"green\">+1.93%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17734562-carnival-corporation-plc-reports-fourth-quarter-and-full-year-earnings\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3527749\" data-linked=\"Carnival EPS beats by $0.11, beats on revenue\" data-tweet=\"$CCL $CUK - Carnival EPS beats by $0.11, beats on revenue https://seekingalpha.com/news/3527749-carnival-eps-beats-0_11-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3527749-carnival-eps-beats-0_11-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527748\" data-ts=\"1576851329\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIAC\" target=\"_blank\">VIAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527748-viacomcbs-acquires-miramax-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ViacomCBS acquires Miramax stake</a></h4><ul><li>ViacomCBS (NASDAQ:<a href='https://seekingalpha.com/symbol/VIAC' title='ViacomCBS Inc.'>VIAC</a>) <a href=\"https://seekingalpha.com/pr/17734512-viacomcbs-to-make-strategic-investment-in-bein-media-group-s-miramax\" target=\"_blank\">announces</a> entering a definitive agreement with beIN Media Group to acquire a 49% stake in Miramax.</li><li>VIAC will pay $375M, which includes a $150M upfront cash payment and a commitment to invest $45M annually over the next five years. The investment will be used for new television and film projects and general working capital.</li><li>ViacomCBS shares are <font color=\"green\">up 1.6%</font> pre-market to $42.62.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527748\" data-linked=\"ViacomCBS acquires Miramax stake\" data-tweet=\"$VIAC - ViacomCBS acquires Miramax stake https://seekingalpha.com/news/3527748-viacomcbs-acquires-miramax-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3527748-viacomcbs-acquires-miramax-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527747\" data-ts=\"1576851150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527747-x-mito-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">X, MITO among premarket losers</a></h4><ul><li>Stealth BioTherapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MITO' title='Stealth BioTherapeutics Corp'>MITO</a>) <font color=\"red\">-56%</font> after <a href=\"https://seekingalpha.com/news/3527718-stealth-bios-elamipretide-flunks-late-stage-pmm-study\" target=\"_blank\">elamipretide flunks</a> late-stage PMM study.</li><li>Valeritas Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a>) <font color=\"red\">-42%</font> on <a href=\"https://seekingalpha.com/pr/17734473-valeritas-experiences-temporary-supply-disruption-resulting-in-revised-preliminary-financial\" target=\"_blank\">announcing</a> revised revenue guidance and preliminary Q4 and FY2019 results.</li><li>Abeona Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a>) <font color=\"red\">-27%</font> on <a href=\"https://seekingalpha.com/news/3527620-abeona-readies-equity-offering-shares-down-27-after-hours\" target=\"_blank\">announcing</a> public offering of common stock and pre-funded warrants.</li><li>Nabriva Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics plc'>NBRV</a>) <font color=\"red\">-18%</font> after <a href=\"https://seekingalpha.com/news/3527673-nabriva-refiles-u-s-contepo-application-shares-up-10-premarket\" target=\"_blank\">refiling</a> U.S. Contepo application.</li><li>Lexicon Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a>) <font color=\"red\">-9%</font> despite <a href=\"https://seekingalpha.com/news/3527695-lexicon-pharmas-zynquista-successful-in-late-stage-t2d-study-shares-up-16-pm\" target=\"_blank\">Zynquista</a> successful in late-stage T2D study.</li><li>CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a>) <font color=\"red\">-8%</font> on <a href=\"https://seekingalpha.com/news/3527619-cymabay-to-cut-60-of-workforce-shares-down-8-after-hours\" target=\"_blank\">terminating</a> 60% of workforce.</li><li>United States Steel (NYSE:<a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/news/3527685-u-s-steelminus-8-on-q4-loss-and-cut-in-dividend\" target=\"_blank\">Q4 loss and cut in dividend</a>.</li><li>F5 Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/FFIV' title='F5 Networks, Inc.'>FFIV</a>) <font color=\"red\">-7%</font> after $1B <a href=\"https://seekingalpha.com/news/3527704-f5minus-5-after-1b-shape-security-purchase\" target=\"_blank\">Shape Security purchase</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527747\" data-linked=\"X, MITO among premarket losers\" data-tweet=\"$MITO $VLRX $ABEO - X, MITO among premarket losers https://seekingalpha.com/news/3527747-x-mito-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527747-x-mito-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527738\" data-ts=\"1576849995\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527738-iac-acquiring-care-com-for-500m-crcmplus-13_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IAC acquiring Care.com for $500M; CRCM +13.5%</a></h4><ul><li>IAC (NASDAQ:<a href='https://seekingalpha.com/symbol/IAC' title='IAC/InterActiveCorp'>IAC</a>) <a href=\"https://seekingalpha.com/pr/17734455-iac-announces-agreement-to-acquire-care-com\" target=\"_blank\">will acquire</a> Care.com (NYSE:<a href='https://seekingalpha.com/symbol/CRCM' title='Care.com, Inc.'>CRCM</a>) for $15 per share in cash.</li><li>The price represents an approximately $500M enterprise value and offers a 34% premium to the closing price on October 25, the last trading day before published M&amp;A speculation.</li><li>IAC executive Tim Allen will become CRCM's new CEO.</li><li>After the expected deal close in Q1, Care.com will no longer trade on the NYSE.</li><li>CRCM shares are <font color=\"green\">up 13.5%</font> pre-market to $15.04.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527738\" data-linked=\"IAC acquiring Care.com for $500M; CRCM +13.5%\" data-tweet=\"$IAC $CRCM - IAC acquiring Care.com for $500M; CRCM +13.5% https://seekingalpha.com/news/3527738-iac-acquiring-care-com-for-500m-crcmplus-13_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3527738-iac-acquiring-care-com-for-500m-crcmplus-13_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527721\" data-ts=\"1576847998\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMQ\" target=\"_blank\">TMQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527721-trilogy-metals-south32-to-partner-on-alaska-project\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trilogy Metals, South32 to partner on Alaska project</a></h4><ul><li>Trilogy Metals (NYSEMKT:<a href='https://seekingalpha.com/symbol/TMQ' title='Trilogy Metals Inc.'>TMQ</a>) <font color=\"green\">+19.4%</font> pre-market after saying South32 (<a href='https://seekingalpha.com/symbol/SOUHY' title='South32 Limited'>OTCPK:SOUHY</a>) exercised its option to <a href=\"https://seekingalpha.com/pr/17734142-south32-and-trilogy-metals-to-form-upper-kobuk-mineral-projects-joint-venture\" target=\"_blank\">buy a 50% interest</a> in a joint venture company that will own the Upper Kobuk Mineral Projects in Alaska.</li><li>TMQ says it will contribute all of its assets associated with the  UKMP and South32 will contribute $145M to the JV.</li><li>The JV will retain $87.5M of the $145M subscription payment to fund its activities and exploration programs  with the balance of $57.5M loaned back to South32.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527721\" data-linked=\"Trilogy Metals, South32 to partner on Alaska project\" data-tweet=\"$TMQ $SOUHY - Trilogy Metals, South32 to partner on Alaska project https://seekingalpha.com/news/3527721-trilogy-metals-south32-to-partner-on-alaska-project?source=tweet\" data-url=\"https://seekingalpha.com/news/3527721-trilogy-metals-south32-to-partner-on-alaska-project\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527720\" data-ts=\"1576847930\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MIK\" target=\"_blank\">MIK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527720-michaelsminus-6-after-morgan-stanley-loses-confidence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Michaels -6% after Morgan Stanley loses confidence</a></h4><ul> <li>Morgan Stanley lowers Michaels (NASDAQ:<a href='https://seekingalpha.com/symbol/MIK' title='The Michaels Companies, Inc.'>MIK</a>) to an Underweight rating after having the retailer slotted at Equal-weight. The ratings cut pivots on broad concerns from MS over sales growth for Michaels and profitability.</li> <li>The firm slides its price target on Michaels to $5 from $7 vs. the <a href=\"https://seekingalpha.com/symbol/MIK/ratings/sell-side-ratings\" target=\"_blank\">average sell-side</a> PT of $7.46.</li> <li>Shares of Michaels are <font color=\"red\">down 5.52%</font> premarket to $6.33 vs. the 52-week trading range of $4.96 to $16.38.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527720\" data-linked=\"Michaels -6% after Morgan Stanley loses confidence\" data-tweet=\"$MIK - Michaels -6% after Morgan Stanley loses confidence https://seekingalpha.com/news/3527720-michaelsminus-6-after-morgan-stanley-loses-confidence?source=tweet\" data-url=\"https://seekingalpha.com/news/3527720-michaelsminus-6-after-morgan-stanley-loses-confidence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527719\" data-ts=\"1576847899\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLI\" target=\"_blank\">CLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527719-mack-caliplus-5_0-after-report-of-udrs-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mack-Cali +5.0% after report of UDR&#39;s interest</a></h4><ul><li>Mack-Cali (NYSE:<a href='https://seekingalpha.com/symbol/CLI' title='Mack-Cali Realty Corporation'>CLI</a>)<font color=\"green\"> jumps 5.0%</font> in premarket trading after Reuters reports that apartment REIT UDR (NYSE:<a href='https://seekingalpha.com/symbol/UDR' title='UDR, Inc.'>UDR</a>)<a href=\"https://www.reuters.com/article/us-mack-cali-rlty-m-a-udr-exclusive/exclusive-property-firm-udr-explores-deal-with-mack-cali-realty-sources-idUSKBN1YN2TR\" target=\"_blank\"> is considering </a>acquiring Mack-Cali Realty, an owner of multifamily rental properties and commercial office space.</li><li>UDR is in talks to partner with Rizk Ventures CEO Thomas Rizk on its bid for Mack-Cali; Rizk was CEO of Mack-Cali from 1997 to 1999 and led Cali Realty before it merged with Mack Company in 1997.</li><li>UDR is interested in the company's residential properties, while Rizk is looking at some of its commercial office space, Reuters reports, citing unnamed sources.</li><li>Citi analyst Michael Bilerman says the deal is unlikely as the transaction would be \"extremely complicated\" with multiple asset types and parties involved.</li><li>Evercore ISI analyst Steve Sakwa, though, says UDR buying CLI would make strategic sense in terms of geographic fit and UDR has the cost of capital to execute the deal on an accretive basis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527719\" data-linked=\"Mack-Cali +5.0% after report of UDR&#39;s interest\" data-tweet=\"$CLI $UDR - Mack-Cali +5.0% after report of UDR&#39;s interest https://seekingalpha.com/news/3527719-mack-caliplus-5_0-after-report-of-udrs-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3527719-mack-caliplus-5_0-after-report-of-udrs-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527718\" data-ts=\"1576847726\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MITO\" target=\"_blank\">MITO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527718-stealth-bios-elamipretide-flunks-late-stage-pmm-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stealth Bio&#39;s elamipretide flunks late-stage PMM study</a></h4><ul><li>Stealth BioTherapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MITO' title='Stealth BioTherapeutics Corp'>MITO</a>) is poised for a significant down move after <a href=\"https://seekingalpha.com/pr/17734361-stealth-biotherapeutics-provides-update-on-phase-3-trial-of-elamipretide-in-primary\" target=\"_blank\">announcing </a>unsuccessful results from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03323749?term=mmpower-3&amp;draw=2&amp;rank=1\" target=\"_blank\">MMPOWER-3</a>, evaluating elamipretide in patients with <a href=\"https://rarediseases.org/physician-guide/mitochondrial-myopathy/\" target=\"_blank\">primary mitochondrial myopathy</a> &#40;PMM&#41;, a group of inherited disorders due to mutations in mitochondrial DNA or nuclear DNA.</li><li>The study failed to achieve the primary endpoints of the change from baseline to week 24 in the six-minute walk test and change from baseline to week 24 in a fatigue scale called PMMSA.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the results.</li><li>Trading, currently suspended, will resume at 8:30 am ET.</li><li><strong>Update</strong>: Shares down <font color=\"red\">59%</font> on resumption of trade.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527718\" data-linked=\"Stealth Bio&#39;s elamipretide flunks late-stage PMM study\" data-tweet=\"$MITO - Stealth Bio&#39;s elamipretide flunks late-stage PMM study https://seekingalpha.com/news/3527718-stealth-bios-elamipretide-flunks-late-stage-pmm-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3527718-stealth-bios-elamipretide-flunks-late-stage-pmm-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527714\" data-ts=\"1576847460\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCON\" target=\"_blank\">TCON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527714-tracon-pharma-up-39-premarket-on-envafolimab-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tracon Pharma up 39% premarket on envafolimab deal</a></h4><ul> <li>TRACON Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TCON' title='TRACON Pharmaceuticals, Inc.'>TCON</a>) is up <font color=\"green\">39%</font> premarket on signing a <a href=\"https://seekingalpha.com/pr/17734305-tracon-pharmaceuticals-3d-medicines-and-jiangsu-alphamab-announce-partnership-for-development\" target=\"_blank\">collaborative partnership agreement</a> with 3D Medicines (Beijing) Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., for the development of envafolimab, also known as KN035, a PD-L1 single-domain antibody administered by subcutaneous injection, for development in soft tissue sarcoma in North America.</li>  <li>TRACON will be responsible for the development and commercialization of envafolimab for sarcoma in North America, except in certain circumstances involving the approval of envafolimab for other indications, in which case TRACON has the option to co-market envafolimab. 3D Medicines and Jiangsu Alphamab will supply envafolimab at pre-negotiated prices.</li>    <li>If TRACON has responsibility for commercialization, it will owe 3D Medicines and Jiangsu Alphamab escalating double digit royalties ranging from the teens to mid-double digits.</li><li>If 3D Medicines and Jiangsu Alphamab have responsibility for commercialization, TRACON will be entitled to (a) double digit royalties if TRACON has chosen to not co-market envafolimab or (b) a 50% royalty if TRACON has chosen to co-market envafolimab in sarcoma.</li>  <li>TRACON intends to initiate a registration enabling study of envafolimab in the sarcoma subtype of UPS in 2020.</li><li>Shares are up <font color=\"green\">39%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3527714\" data-linked=\"Tracon Pharma up 39% premarket on envafolimab deal\" data-tweet=\"$TCON - Tracon Pharma up 39% premarket on envafolimab deal https://seekingalpha.com/news/3527714-tracon-pharma-up-39-premarket-on-envafolimab-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3527714-tracon-pharma-up-39-premarket-on-envafolimab-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527710\" data-ts=\"1576847001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MITO\" target=\"_blank\">MITO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527710-stealth-biotherapeutics-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stealth BioTherapeutics halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Stealth BioTherapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MITO' title='Stealth BioTherapeutics Corp'>MITO</a>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527710\" data-linked=\"Stealth BioTherapeutics halted pending news\" data-tweet=\"$MITO - Stealth BioTherapeutics halted pending news https://seekingalpha.com/news/3527710-stealth-biotherapeutics-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3527710-stealth-biotherapeutics-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527707\" data-ts=\"1576846887\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHNG\" target=\"_blank\">CHNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527707-raymond-james-likes-change-healthcare-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raymond James likes Change Healthcare in premarket analyst action</a></h4><ul><li>Change Healthcare (NASDAQ:<a href='https://seekingalpha.com/symbol/CHNG' title='Change Healthcare Inc.'>CHNG</a>) initiated with Outperform rating and $18 (23% upside) price target at Raymond James.</li><li>Health Catalyst (NASDAQ:<a href='https://seekingalpha.com/symbol/HCAT' title='Health Catalyst, Inc.'>HCAT</a>) initiated with Strong Buy rating and $46 (52% upside) price target at Raymond James.</li><li>HealthStream (NASDAQ:<a href='https://seekingalpha.com/symbol/HSTM' title='HealthStream, Inc.'>HSTM</a>) initiated with Market Perform rating at Raymond James.</li><li>Immunomedics (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a>) initiated with Buy rating and $26 (30% upside) price target at BofA Global Research.</li><li>Marinus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals, Inc.'>MRNS</a>) initiated with Outperform rating and $6 (400% upside) price target at Oppenheimer.</li><li>Medical Properties Trust (NYSE:<a href='https://seekingalpha.com/symbol/MPW' title='Medical Properties Trust, Inc.'>MPW</a>) initiated with Buy rating and $25 (23% upside) price target at Mizuho Securities.</li><li>Omega Healthcare Investors (NYSE:<a href='https://seekingalpha.com/symbol/OHI' title='Omega Healthcare Investors, Inc.'>OHI</a>) initiated with Buy rating and $50 (21% upside) price target at Mizuho.</li><li>Phreesia (NYSE:<a href='https://seekingalpha.com/symbol/PHR' title='Phreesia, Inc.'>PHR</a>) initiated with Outperform rating and $33 (27% upside) price target at Raymond James.</li><li>Physicians Realty Trust (NYSE:<a href='https://seekingalpha.com/symbol/DOC' title='Physicians Realty Trust'>DOC</a>) initiated with Buy rating and $20 (7% upside) price target at Mizuho.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527707\" data-linked=\"Raymond James likes Change Healthcare in premarket analyst action\" data-tweet=\"$CHNG $HCAT $HSTM - Raymond James likes Change Healthcare in premarket analyst action https://seekingalpha.com/news/3527707-raymond-james-likes-change-healthcare-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3527707-raymond-james-likes-change-healthcare-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527705\" data-ts=\"1576846136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPR\" target=\"_blank\">SPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527705-spirit-aerosystems-evaluating-all-potential-actions-737-max-suspended\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spirit AeroSystems &#39;evaluating all potential actions&#39; as 737 MAX suspended</a></h4><ul><li>Spirit AeroSystems (NYSE:<a href='https://seekingalpha.com/symbol/SPR' title='Spirit AeroSystems Holdings, Inc.'>SPR</a>) <font color=\"red\">-2.4%</font> pre-market after confirming it will <a href=\"https://seekingalpha.com/pr/17734328-spirit-aerosystems-to-suspend-boeing-737-max-production-in-january-2020\" target=\"_blank\">suspend production</a> of the 737 MAX jetliner starting Jan. 1.</li><li>SPR says it is \"evaluating all potential actions to align its cost base with lower production levels expected in 2020,\" as revenue from 737 aircraft components represents more than 50% of the company's annual revenue.</li><li>Shares have slid 6% this week following <a href=\"https://seekingalpha.com/news/3526652-boeing-confirms-737-max-production-halt-in-january\" target=\"_blank\">Boeing's initial announcement</a> that it would suspend production of the plane.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527705\" data-linked=\"Spirit AeroSystems &#39;evaluating all potential actions&#39; as 737 MAX suspended\" data-tweet=\"$SPR - Spirit AeroSystems &#39;evaluating all potential actions&#39; as 737 MAX suspended https://seekingalpha.com/news/3527705-spirit-aerosystems-evaluating-all-potential-actions-737-max-suspended?source=tweet\" data-url=\"https://seekingalpha.com/news/3527705-spirit-aerosystems-evaluating-all-potential-actions-737-max-suspended\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527704\" data-ts=\"1576846120\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FFIV\" target=\"_blank\">FFIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527704-f5minus-5-after-1b-shape-security-purchase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">F5 -5% after $1B Shape Security purchase</a></h4><ul><li>Yesterday, F5 Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/FFIV' title='F5 Networks, Inc.'>FFIV</a>) <a href=\"https://seekingalpha.com/pr/17734046-f5-to-acquire-shape-security-transforming-application-security\" target=\"_blank\">announced</a> the $1B in cash acquisition of Shape Security, which sells a fraud prevention platform to banks.</li><li>Jefferies maintains a Hold rating and lowers its price target from $150 to $135.</li><li>The firm thinks the purchase makes strategic sense, but \"it\u2019s hard to ignore the $16.54/share in departing Balance Sheet cash without any 2020/2021 EPS benefit in return.\"</li><li>Piper Jaffray (Overweight, $168 target) sees the deal as positive and remains optimistic about F5's strategic vision and FCF accretion. The firm does expect F5 to initially trade down due to the earnings impact.</li><li>F5 shares are <font color=\"red\">down 5.4%</font> pre-market to $135.90. The company has a Neutral average <a href=\"https://seekingalpha.com/symbol/FFIV/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527704\" data-linked=\"F5 -5% after $1B Shape Security purchase\" data-tweet=\"$FFIV - F5 -5% after $1B Shape Security purchase https://seekingalpha.com/news/3527704-f5minus-5-after-1b-shape-security-purchase?source=tweet\" data-url=\"https://seekingalpha.com/news/3527704-f5minus-5-after-1b-shape-security-purchase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527702\" data-ts=\"1576845647\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/K\" target=\"_blank\">K</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527702-kelloggplus-1-after-two-notch-baml-lift\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kellogg +1% after two-notch BAML lift</a></h4><ul> <li>Bank of America Merrill Lynch lifts Kellogg (NYSE:<a href='https://seekingalpha.com/symbol/K' title='Kellogg Company'>K</a>) straight to a Buy rating after having the food stock slotted at Underperform.</li> <li>The firm assigns a price target of $75 to rep 12% upside potential.</li><li>The capitulation from BAML on Kellogg follow closely after a solid earnings report posted by General Mills.</li> <li>Shares of BAML are <font color=\"green\">up 0.90%</font> to $67.38 in premarket action and look likely to open above their 52-week high set yesterday of $67.13.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527702\" data-linked=\"Kellogg +1% after two-notch BAML lift\" data-tweet=\"$K - Kellogg +1% after two-notch BAML lift https://seekingalpha.com/news/3527702-kelloggplus-1-after-two-notch-baml-lift?source=tweet\" data-url=\"https://seekingalpha.com/news/3527702-kelloggplus-1-after-two-notch-baml-lift\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527695\" data-ts=\"1576844959\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LXRX\" target=\"_blank\">LXRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527695-lexicon-pharmas-zynquista-successful-in-late-stage-t2d-study-shares-up-16-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lexicon Pharma&#39;s Zynquista successful in late-stage T2D study; shares up 16% PM</a></h4><ul><li>A Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03351478?intr=Sotagliflozin&amp;titles=sota-empa&amp;phase=2&amp;draw=2&amp;rank=1\" target=\"_blank\">SOTA-EMPA</a>, evaluating Lexicon Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a>) Zynquista (sotagliflozin) in patients with type 2 diabetes (T2D) <a href=\"https://seekingalpha.com/pr/17734289-lexicon-pharmaceuticals-announces-topline-phase-3-data-for-sotagliflozin-in-type-2-diabetes\" target=\"_blank\">met the primary endpoint</a> demonstrating its superiority versus placebo in lowering HbA1C levels at week 26.</li><li>A secondary endpoint of non-inferiority to empagliflozin was also met.</li><li>No new safety signals were reported.</li><li>SOTA-EMPA, conducted by former licensee Sanofi, is the fourth of nine core late-stage studies in the sotagliflozin T2D program.</li><li>Complete results will be submitted for presentation at future medical conferences.</li><li>Shares up <font color=\"green\">16%</font> premarket on robust volume.</li><li><strong>Update</strong>: Shares have reversed, down <font color=\"red\">6%</font>, apparently due to its failure to demonstrate superiority over Eli Lilly's (<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color=\"green\">+1.7%</font>) Jardiance (empagliflozin).</li></ul><div class=\"tiny-share-widget\" data-id=\"3527695\" data-linked=\"Lexicon Pharma&#39;s Zynquista successful in late-stage T2D study; shares up 16% PM\" data-tweet=\"$LXRX $LLY - Lexicon Pharma&#39;s Zynquista successful in late-stage T2D study; shares up 16% PM https://seekingalpha.com/news/3527695-lexicon-pharmas-zynquista-successful-in-late-stage-t2d-study-shares-up-16-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3527695-lexicon-pharmas-zynquista-successful-in-late-stage-t2d-study-shares-up-16-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527690\" data-ts=\"1576844223\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WGO\" target=\"_blank\">WGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527690-winnebagoplus-6-after-earnings-topper\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Winnebago +6% after earnings topper</a></h4><ul> <li>Winnebago (NYSE:<a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a>) reports it churned up adjusted EBITDA of $42M in <a href=\"https://seekingalpha.com/pr/17734282-winnebago-industries-announces-first-quarter-fiscal-2020-results\" target=\"_blank\">FQ1</a> to top the consensus mark of $38M. EBITDA was up 9.2% from a year ago off a 19% increase in overall sales.</li> <li>Revenue from the towable segment was up 16.5% to $341M, while revenue from the motorhome segment jumped 24.6%.</li> <li>Gross profit margin fell 100 bps during the quarter due chiefly to a change in mix as a result of the acquisition of Newmar and the impact of the associated purchase accounting. EPS fell 44% Y/Y to $0.44.</li> <li>Cash flow from operations during the quarter rose 45.9% to $79.0M.</li><li>CEO outlook: \"Our continued growth reflects our competitive position in the RV industry and the resilience of our diversified portfolio, which has positioned us well to deliver solid results despite prevailing industry headwinds. As we look ahead to the balance of Fiscal 2020, we remain focused on authentically differentiating ourselves from the competition around quality, customer service and innovation.\"</li> <li>Shares of Winnebago are <font color=\"green\">up 5.92%</font> premarket to $50.99.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527682-winnebago-eps-beats-0_14-beats-on-revenue\" target=\"_blank\">Winnebago EPS beats by $0.14, beats on revenue</a> (Dec. 20)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527690\" data-linked=\"Winnebago +6% after earnings topper\" data-tweet=\"$WGO - Winnebago +6% after earnings topper https://seekingalpha.com/news/3527690-winnebagoplus-6-after-earnings-topper?source=tweet\" data-url=\"https://seekingalpha.com/news/3527690-winnebagoplus-6-after-earnings-topper\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527688\" data-ts=\"1576843993\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527688-blackberryplus-5_7-after-q3-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackBerry +5.7% after Q3 beats</a></h4><ul><li>BlackBerry (NYSE:<a href='https://seekingalpha.com/symbol/BB' title='BlackBerry Limited'>BB</a>) <font color=\"green\">+5.7%</font> <a href=\"https://seekingalpha.com/news/3527683-blackberry-eps-beats-0_01-beats-on-revenue\" target=\"_blank\">reports Q3 beats</a> with revenue up 23% Y/Y. Software and services revenue was up 26% to $275M.</li><li>Adjusted gross margin was 74.2% compared to the 75.2% in last year's quarter.</li><li>BB generated $37M in FCF in the quarter. Cash from operations was $40M and capex totaled $3M.</li><li>FY20 will come on the earnings call at 8 AM with a webcast <a href=\"https://www.blackberry.com/us/en/company/investors\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17734300-blackberry-reports-fiscal-2020-third-quarter-results\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527688\" data-linked=\"BlackBerry +5.7% after Q3 beats\" data-tweet=\"$BB - BlackBerry +5.7% after Q3 beats https://seekingalpha.com/news/3527688-blackberryplus-5_7-after-q3-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3527688-blackberryplus-5_7-after-q3-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527685\" data-ts=\"1576843425\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/X\" target=\"_blank\">X</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527685-u-s-steelminus-8-on-q4-loss-and-cut-in-dividend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Steel -8% on Q4 loss and cut in dividend</a></h4><ul><li>\"The current realities of the markets we serve are having a significant impact on our short-term results,\" said CEO David Burritt, who then promised \"swift action\" to align the company's operational footprint and financial strategy with new realities.</li><li>\"Fourth quarter expected results confirm the need to change to make the business more resistant to factors outside of our control.\"</li><li>Q4 adjusted loss per share is seen at about $1.15M (excludes $225M in restructuring charges). The dividend is being cut to a penny from a nickel.</li><li><a href=\"https://seekingalpha.com/pr/17734130-united-states-steel-corporation-provides-fourth-quarter-and-full-year-2019-guidance\" target=\"_blank\">More here</a></li><li><a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color=\"red\">-7.8%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3527685\" data-linked=\"U.S. Steel -8% on Q4 loss and cut in dividend\" data-tweet=\"$X - U.S. Steel -8% on Q4 loss and cut in dividend https://seekingalpha.com/news/3527685-u-s-steelminus-8-on-q4-loss-and-cut-in-dividend?source=tweet\" data-url=\"https://seekingalpha.com/news/3527685-u-s-steelminus-8-on-q4-loss-and-cut-in-dividend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>92&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527683\" data-ts=\"1576843336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527683-blackberry-eps-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackBerry EPS beats by $0.01, beats on revenue</a></h4><ul><li>BlackBerry (NYSE:<a href='https://seekingalpha.com/symbol/BB' title='BlackBerry Limited'>BB</a>): Q3 Non-GAAP EPS of $0.03 <font color=\"green\">beats by $0.01</font>; GAAP EPS of -$0.07.</li><li>Revenue of $280M (+22.8% Y/Y) <font color=\"green\">beats by $3.69M</font>.</li><li>Shares <font color=\"green\">+8.4%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17734300-blackberry-reports-fiscal-2020-third-quarter-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3527683\" data-linked=\"BlackBerry EPS beats by $0.01, beats on revenue\" data-tweet=\"$BB - BlackBerry EPS beats by $0.01, beats on revenue https://seekingalpha.com/news/3527683-blackberry-eps-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3527683-blackberry-eps-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527679\" data-ts=\"1576843184\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMX\" target=\"_blank\">KMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527679-carmaxplus-1-after-sales-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CarMax +1% after sales beat</a></h4><ul> <li>CarMax (NYSE:<a href='https://seekingalpha.com/symbol/KMX' title='CarMax, Inc.'>KMX</a>) reports total used unit sales rose 11.0% in <a href=\"https://seekingalpha.com/pr/17734266-carmax-reports-third-quarter-results\" target=\"_blank\">Q3</a> and comparable store used unit increased 7.5%.</li> <li>The company says the strong level of sales was supported by growth in web traffic and favorable consumer response to consumer initiatives, which both supported conversions.</li> <li>Gross margin fell 50 bps Y/Y to 12.8% of sales to miss the consensus estimate of 13.2%.</li> <li>Shares of CarMax are <font color=\"green\">up 1.28%</font> to $100.05.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527676-carmax-eps-misses-0_12-beats-on-revenue\" target=\"_blank\">CarMax EPS misses by $0.12, beats on revenue</a> (Dec. 20)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527679\" data-linked=\"CarMax +1% after sales beat\" data-tweet=\"$KMX - CarMax +1% after sales beat https://seekingalpha.com/news/3527679-carmaxplus-1-after-sales-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3527679-carmaxplus-1-after-sales-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527673\" data-ts=\"1576842276\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBRV\" target=\"_blank\">NBRV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527673-nabriva-refiles-u-s-contepo-application-shares-up-10-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nabriva refiles U.S. Contepo application; shares up 10% premarket</a></h4><ul><li>Nabriva Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics plc'>NBRV</a>) is up <font color=\"green\">10%</font> premarket on light volume in reaction to its <a href=\"https://seekingalpha.com/pr/17734244-nabriva-therapeutics-resubmits-new-drug-application-for-intravenous-contepo-fosfomycin-for\" target=\"_blank\">resubmission</a> of a U.S. marketing application for Contepo (fosfomycin) for injection for the treatment of complicated urinary tract infections (cUTIs), including acute pyelonephritis. It anticipates a six-month review period by the FDA.</li><li>The company <a href=\"https://seekingalpha.com/news/3456860-fda-rejects-nabrivas-contepo-application-shares-down-28-premarket\" target=\"_blank\">received a CRL</a> in May citing deficiencies at one of its contract manufacturers.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527673\" data-linked=\"Nabriva refiles U.S. Contepo application; shares up 10% premarket\" data-tweet=\"$NBRV - Nabriva refiles U.S. Contepo application; shares up 10% premarket https://seekingalpha.com/news/3527673-nabriva-refiles-u-s-contepo-application-shares-up-10-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3527673-nabriva-refiles-u-s-contepo-application-shares-up-10-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":55,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}